You are here

Share:

Search Technologies

Showing 101-103 of 103 results found

Nanoparticle delivery of lung cancer therapeutic

The National Cancer Institute seeks parties interested in licensing an improved treatment for non-small cell lung cancer based on inhalation of nano- and microparticle therapeutics.

High Affinity Monoclonal Antibodies Targeting Glypican-1

Researchers at the National Cancer Institute (NCI) have isolated two Glypican-1- (GPC1)- specific antibodies: the mouse monoclonal antibody HM2 that binds the C-lobe of GPC1 close to the cell surface, and the camel single domain antibody D4. The D4 single domain antibody (also called ‘nanobody’) has a high affinity for GPC1-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.

Pages